ILC Dover

Engineering Efficiency and Containment in Modern Therapeutic Manufacturing The rapid evolution of biopharmaceutical pipelines driven by biologics, cell and gene therapies, and high-potency compounds has placed unprecedented demands on manufacturing systems. Facilities are under continuous pressure to improve speedto-market, ensure operator safety, and maintain strict contamination control, all while navigating increasingly complex regulatory expectations.

Within this environment, the importance of engineered containment and single-use technologies has expanded significantly. These solutions are no longer viewed as incremental improvements; they are now critical enablers of modern therapeutic manufacturing.

ILC Dover, an Ingersoll Rand business, has been at the forefront of this shift, supporting life sciences manufacturers with engineered solutions designed to improve process efficiency and mitigate risk across the production lifecycle.

Rising Complexity in Bioprocessing

Biopharmaceutical manufacturing is undergoing a structural transformation. Therapeutic modalities have evolved from traditional small molecules to include monoclonal antibodies, antibody-drug conjugates (ADCs), mRNA-based therapeutics,

and personalised cell and gene therapies. Each of these modalities introduces distinct processing and containment challenges.

For example, highly potent active pharmaceutical ingredients (HPAPIs) require robust containment strategies to protect operators and prevent environmental exposure. At the same time, advanced biologics manufacturing demands strict control of sterile conditions to avoid cross-contamination and ensure product integrity.

This convergence of potency and sterility requirements has increased reliance on flexible containment solutions and closed processing systems. Manufacturers are seeking technologies that can maintain high levels of control while supporting operational agility.

The Role of Single-Use Technologies

Single-use systems have become a cornerstone of modern bioprocessing strategies. Their adoption is driven by several well-documented benefits, including reduced cleaning validation requirements, faster turnaround times, and improved flexibility in multi-product facilities.

In powder and liquid handling applications, singleuse solutions also offer significant advantages in minimising cross-contamination risk and enabling safer handling of hazardous materials. These capabilities are particularly important in facilities working with potent compounds or small-batch, high-value therapeutics.

However, the shift toward single-use is not without challenges. Integration into existing workflows, material compatibility, waste management considerations, and operator training all require careful planning. As a result, manufacturers increasingly look to solution providers not only for products but also for expertise in system design and implementation.

Containment as a Process Enabler

Historically, containment has often been treated as a compliance requirement and necessary component of facility design to meet occupational safety standards. Today, this perspective is changing.

Containment is increasingly viewed as a process enabler that can directly impact productivity and product quality.

Advanced containment systems, including flexible isolators and closed transfer solutions, allow manufacturers to handle potent or sensitive materials without compromising process efficiency.

By reducing exposure risks and minimising contamination pathways, these technologies support more consistent and reliable operations.

In addition, well-designed containment solutions can streamline workflows by reducing the need for extensive personal protective equipment (PPE) and simplifying material transfer steps. This can translate into shorter process times and improved operator ergonomics factors that are gaining importance as labour shortages and operational efficiency remain key industry concerns.

Integration Across the Workstream

One of the key challenges in modern manufacturing is ensuring that individual process improvements translate into overall efficiency gains. Optimising a single unit operation in isolation can sometimes create bottlenecks elsewhere in the workflow.

To address this, there is growing emphasis on integrated solutions that consider the full manufacturing workstream, from material handling and upstream processing to downstream purification and final fill.

Providers with a systems-level understanding of bioprocessing are better positioned to identify interdependencies and design solutions that align with end-to-end process requirements.

This approach helps minimise disruptions, improve scalability, and support more seamless technology transfer between development and commercial manufacturing.

ILC Dover has positioned itself within this context as a provider of integrated solutions, leveraging experience across multiple process stages to support holistic workflow optimisation.

Supporting Advanced Therapies

The rise of advanced therapies, including cell and gene treatments, is introducing new technical and operational challenges. These therapies often involve small batch sizes, high product value, and complex handling requirements, making traditional large-scale manufacturing approaches less applicable.

Flexible, modular systems are therefore essential.

Single-use containment solutions can support the scalability and adaptability needed for these therapies, enabling manufacturers to operate efficiently while maintaining stringent quality standards.

In addition, the handling of viral vectors, genetically modified cells, and highly potent compounds requires precise control of both containment and sterility. This places further emphasis on engineered solutions that can meet dual requirements without adding unnecessary complexity to the process.

Digitalisation and Future Manufacturing Trends

Looking ahead, several key trends are expected to shape the future of therapeutic manufacturing: • • • •

Digital integration and process analytics to improve visibility and control Modular facility design to support flexible production capacity Sustainability considerations, particularly in relation to single-use systems Expansion of decentralised and regional manufacturing models

These trends will further increase the need for adaptable, efficient, and integrated solutions.

Manufacturers will require technologies that not only meet current demands but can also evolve alongside changing production paradigms.

Balancing Innovation and Compliance

As innovation accelerates, regulatory expectations continue to evolve in parallel. Agencies are placing greater emphasis on risk-based approaches, quality by design (QbD), and lifecycle management.

This creates a dynamic environment in which manufacturers must continuously balance innovation with compliance. Engineering solutions that are robust, validated, and well-documented play a critical role in achieving this balance.

Solution providers that can demonstrate a deep understanding of regulatory requirements while delivering technologies that enhance performance will remain key partners in the industry.

Conclusion

The expansion of GLP 1 therapies, alongside continued innovation in advanced modalities, is redefining expectations for pharmaceutical manufacturing. Contract development and manufacturing organisations (CDMOs) are at the centre of this shift, facing increasing pressure to deliver both scalability and flexibility while maintaining stringent standards for safety, quality, and regulatory compliance.

For CDMOs, this challenge is particularly acute.

Facilities must support a diverse client base, manage multiple products with varying containment requirements, and scale production rapidly from

clinical batches to commercial volumes - often within the same infrastructure. This places greater emphasis on adaptable technologies that can streamline changeovers, reduce cross-contamination risk, and ensure consistent performance across campaigns.

Containment and single-use technologies have emerged as key enablers in this environment. They allow CDMOs to operate closed, flexible systems that can be deployed quickly, reconfigured efficiently, and validated with reduced complexity. This not only improves operational efficiency but also enhances the ability to meet tight client timelines and evolving regulatory expectations.

Within this context, ILC Dover supports CDMOs by providing engineered solutions specifically designed for multi-product, high-mix manufacturing environments. Its portfolio of flexible containment systems and single-use technologies enables safe handling of both high-potency and high-volume materials, while minimising downtime associated with cleaning and changeover.

By integrating containment into single-use workflows, ILC Dover helps CDMOs achieve: • • • •

Improved facility utilisation through faster batch turnaround Reduced risk of cross-contamination across client programmes Scalable solutions that transition from development to commercial manufacturing Enhanced operator safety and process consistency

About ILC Dover, Part of Ingersoll Rand Today, ILC Dover (an Ingersoll Rand business) delivers a broad portfolio that includes flexible containment systems, single-use bioprocessing solutions, bulk packaging, inflatable structures, and personal protective equipment. These solutions are designed to protect people, products, and critical infrastructure in hazardous conditions, supporting industries that require high levels of safety, contamination control, and operational efficiency Driven by innovation and customer-centric design, ILC Dover partners with organisations globally to solve complex technical challenges - particularly in life sciences manufacturing and advanced aerospace applications - while enabling safer, more efficient processes.

Equally important, ILC Dover’s partnership-driven approach aligns with the CDMO business model.

By working closely with customers to understand process requirements and facility constraints, the company helps design solutions that integrate seamlessly into existing operations rather than requiring extensive reconfiguration.

As therapeutic pipelines continue to diversify, spanning high-growth products such as GLP 1 therapies alongside advanced modalities, CDMOs will play an increasingly critical role in global manufacturing capacity. Supporting this evolution requires technologies that combine flexibility, containment, and efficiency within a unified framework.

Through its expertise in engineered containment and single-use systems, ILC Dover is positioned to support CDMOs in meeting these demands, enabling more agile operations, improved scalability, and the reliable delivery of life-saving therapies to patients worldwide.

CONTACT US

PRODUCED BY APAC OUTLOOK MAGAZINE